Grand Pharmaceutical Group Ltd. has provided an update regarding its acquisition of the entire equity interests in Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. The transaction consideration is set at RMB316 million, determined through arm's length negotiations and based on factors such as the financial performance and business prospects of the target companies. Recent financial figures show the target companies reported combined revenues of RMB238.6 million in 2025 and RMB220.2 million in 2024, with net profits after tax of RMB35.8 million and RMB15.0 million for those respective years. The company also clarified that 17 comparable public companies were reviewed in determining the transaction terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260203-12011545), on February 03, 2026, and is solely responsible for the information contained therein.